Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2020, with the SEC on April 23, 2021. This document is available on Gracell's investor relations website and the SEC's site. The company focuses on developing innovative cell therapies to address challenges in CAR-T treatments. Gracell aims to provide significant advancements in the field by overcoming issues such as long manufacturing times and high costs. Shareholders can request a hard copy of the report free of charge.

Positive

• Filing of Form 20-F enhances transparency and compliance with SEC regulations.
• Gracell's focus on innovative therapies addresses significant challenges in CAR-T treatments.

Negative

• None.

SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission (“SEC”) on April 23, 2021.

The annual report is available on the company’s investor relations website at ir.gracellbio.com and on the SEC’s website at www.sec.gov. The company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, Gracell Biotechnologies, Building 3, 418 Guilin Road, XuHui District, Shanghai, 200233, People’s Republic of China.

About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com

Cautionary Noted Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing date of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the final prospectus filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Gracell specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

FAQ

What is the significance of Gracell's annual report filed on April 23, 2021?

The annual report provides crucial insights into Gracell's financial performance and compliance with SEC regulations.

How can shareholders access Gracell's annual report?

Shareholders can view the report on Gracell's investor relations website or request a hard copy free of charge.

What are Gracell's main technology platforms?

Gracell uses FasTCAR and TruUCAR technology platforms to develop its cell therapies.

What challenges does Gracell aim to overcome with its therapies?

Gracell aims to address lengthy manufacturing times, high costs, and the lack of effective CAR-T therapies for solid tumors.

What is the ticker symbol for Gracell Biotechnologies?

Gracell Biotechnologies is traded under the ticker symbol GRCL on NASDAQ.